IN186596B - - Google Patents

Info

Publication number
IN186596B
IN186596B IN104CA1996A IN186596B IN 186596 B IN186596 B IN 186596B IN 104CA1996 A IN104CA1996 A IN 104CA1996A IN 186596 B IN186596 B IN 186596B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Rodes Montserrat Ballester
Boven Marinus Van
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN186596(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of IN186596B publication Critical patent/IN186596B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN104CA1996 1995-02-01 1996-01-22 IN186596B (enEXAMPLES)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.

Publications (1)

Publication Number Publication Date
IN186596B true IN186596B (enEXAMPLES) 2001-10-06

Family

ID=8289322

Family Applications (1)

Application Number Title Priority Date Filing Date
IN104CA1996 IN186596B (enEXAMPLES) 1995-02-01 1996-01-22

Country Status (20)

Country Link
US (1) US5626875A (enEXAMPLES)
EP (2) EP0773025B1 (enEXAMPLES)
JP (1) JP4183746B2 (enEXAMPLES)
KR (1) KR100331290B1 (enEXAMPLES)
AR (1) AR002702A1 (enEXAMPLES)
AT (2) ATE193649T1 (enEXAMPLES)
AU (1) AU4540396A (enEXAMPLES)
CA (1) CA2184842C (enEXAMPLES)
DE (3) DE69634613T2 (enEXAMPLES)
DK (2) DK0993830T3 (enEXAMPLES)
ES (3) ES2094694B1 (enEXAMPLES)
FI (1) FI121730B (enEXAMPLES)
HU (1) HU229219B1 (enEXAMPLES)
IL (1) IL116673A (enEXAMPLES)
IN (1) IN186596B (enEXAMPLES)
PT (2) PT993830E (enEXAMPLES)
SI (2) SI0773025T1 (enEXAMPLES)
TW (1) TW503115B (enEXAMPLES)
WO (1) WO1996023500A1 (enEXAMPLES)
ZA (1) ZA96683B (enEXAMPLES)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HU227566B1 (en) * 1995-09-21 2011-08-29 Pharma Pass Llc Acid-labile pharmaceutical composition containing omeprazole and process for its preparation
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
EP1004305B1 (en) * 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
EP1105105B1 (en) * 1998-08-12 2006-03-29 ALTANA Pharma AG Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
HU229213B1 (en) 1999-10-20 2013-09-30 Eisai R & D Man Co Ltd Bunkyo Ku Method for stabilizing benzimidazole compounds
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
DE69925740T2 (de) * 1999-12-16 2006-05-11 Laboratorio Medinfar-Produtos Farmacéuticos, S. A. Neue stabile mehreinheitliche substituierte Benzimidazole enthaltende pharmazeutische Präparate
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
JP2004520275A (ja) * 2000-11-10 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー 加水分解的に不安定な組成物
WO2002098422A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
EP1409478B1 (en) 2001-07-16 2006-03-29 Janssen Pharmaceutica N.V. Improved process for preparing benzimidazole-type compounds
BR0206086A (pt) * 2001-09-28 2003-12-23 Mcneil Ppc Inc Formas de dosagem de liberação modificada
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
PL208130B1 (pl) * 2002-08-02 2011-03-31 Ratiopharm Gmbh Preparat farmaceutyczny zawierający związek benzoimidazolu w mieszaninie z celulozą mikrokrystaliczną oraz sposób jego otrzymywania
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
BRPI0409125A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
JP2006522818A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド メチルナルトレキソンを含む医薬処方物
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
AU2003245033A1 (en) * 2003-05-08 2004-11-26 Podili Khadgapathi An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
JP2007536349A (ja) 2004-05-07 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の医薬剤形及び製造方法
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP1830822A1 (en) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
WO2007075980A2 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
EP2046334B1 (en) * 2006-07-25 2014-05-21 Vecta Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
MX2009010552A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Antagonistas de receptor de opioide periferico y usos de los mismos.
EP2240489A1 (en) * 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
US20110150945A1 (en) * 2008-08-11 2011-06-23 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
HRP20180567T1 (hr) * 2011-11-02 2018-05-18 Laboratorios Del Dr. Esteve, S.A. Farmaceutski pripravak omeprazola
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
JP6686013B2 (ja) 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) * 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
CA2184842C (en) 2007-08-07
ES2148725T3 (es) 2000-10-16
EP0993830B1 (en) 2005-04-13
DK0993830T3 (da) 2005-08-08
DE69634613D1 (de) 2005-05-19
CA2184842A1 (en) 1996-08-08
EP0773025B1 (en) 2000-06-07
ES2094694B1 (es) 1997-12-16
HUP9603014A3 (en) 2000-12-28
EP0773025A1 (en) 1997-05-14
PT993830E (pt) 2005-06-30
HUP9603014A2 (hu) 1998-03-30
ES2094694A1 (es) 1997-01-16
FI963916A0 (fi) 1996-09-30
PT773025E (pt) 2000-10-31
JPH09511257A (ja) 1997-11-11
DE69608767D1 (de) 2000-07-13
DE29623938U1 (de) 2000-10-05
FI963916L (fi) 1996-09-30
ZA96683B (en) 1997-09-23
DE69634613T2 (de) 2006-03-09
KR100331290B1 (ko) 2002-11-22
ATE193649T1 (de) 2000-06-15
AU4540396A (en) 1996-08-21
DK0773025T3 (da) 2000-10-09
IL116673A (en) 2000-10-31
IL116673A0 (en) 1996-05-14
HU229219B1 (en) 2013-09-30
ES2238796T3 (es) 2005-09-01
FI121730B (fi) 2011-03-31
WO1996023500A1 (es) 1996-08-08
EP0993830A3 (en) 2001-10-04
TW503115B (en) 2002-09-21
JP4183746B2 (ja) 2008-11-19
SI0993830T1 (en) 2005-10-31
AR002702A1 (es) 1998-04-29
ATE292967T1 (de) 2005-04-15
SI0773025T1 (en) 2000-10-31
EP0993830A2 (en) 2000-04-19
US5626875A (en) 1997-05-06

Similar Documents

Publication Publication Date Title
BR122012014331A2 (enEXAMPLES)
BRPI9612258B1 (enEXAMPLES)
IN186596B (enEXAMPLES)
BRPI9612138B1 (enEXAMPLES)
CH0741373H1 (enEXAMPLES)
BR7501503U (enEXAMPLES)
BR7502120U (enEXAMPLES)
CN3032332S (enEXAMPLES)
CN3032692S (enEXAMPLES)
CN3029928S (enEXAMPLES)
CN3030154S (enEXAMPLES)
CN3030197S (enEXAMPLES)
CN3030225S (enEXAMPLES)
CN3030296S (enEXAMPLES)
CN3030415S (enEXAMPLES)
CN3030489S (enEXAMPLES)
CN3030542S (enEXAMPLES)
CN3030543S (enEXAMPLES)
CN3030760S (enEXAMPLES)
CN3031001S (enEXAMPLES)
CN3031350S (enEXAMPLES)
CN3031655S (enEXAMPLES)
CN3031742S (enEXAMPLES)
CN3031926S (enEXAMPLES)
BY5258C1 (enEXAMPLES)